PharmiWeb40m
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
BioWorld10h
Stereotaxis begins anew with Genesisx launch in EU
Continuing a cascade of positive news for Stereotaxis Inc., the company reported the first order for its petite Genesisx robot in Europe. The system received CE mark in August, but management held off ...